December 5, 2024 11:33 AM EST
R&D

Pro­tara’s stock near­ly dou­bles as biotech di­vulges new blad­der can­cer da­ta

Lei Lei Wu

News Reporter

Pro­tara Ther­a­peu­tics re­port­ed that 13 of 18 blad­der can­cer pa­tients who re­ceived its ex­per­i­men­tal cell ther­a­py saw no signs of their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cal­i­co, De­nal­i's ALS drugs miss pri­ma­ry ob­jec­tives in bas­ket study

Ver­tex signs in vi­vo gene edit­ing de­liv­ery pact for sick­le cell and tha­lassemia as it looks be­yond Cas­gevy

Met­sera’s long-act­ing GLP-1 looks com­pet­i­tive in Phase 2 obe­si­ty study

Ex­clu­sive: Aven­zo picks up an­oth­er ADC, this time with mul­ti-part­nered Du­al­i­ty­Bio

Ken Song's Can­did li­cens­es a T cell en­gager from WuXi Bio

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

A service from the Financial Times